LISA MCBRYAR: Open Payments
NPI 1205954021 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,518 in 128 payments from 16 companies in 2025. Trend: 2023 $2,245 · 2024 $1,999 · 2025 $2,518
Food & beverage: $2,518
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 13 | $418 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $371 |
| Axsome Therapeutics, Inc. | 9 | $236 |
| Otsuka America Pharmaceutical, Inc. | 10 | $218 |
| Alkermes, Inc. | 11 | $211 |
| Vanda Pharmaceuticals Inc. | 11 | $199 |
| ABBVIE INC. | 18 | $194 |
| Lundbeck LLC | 6 | $155 |
| Noven Therapeutics, LLC | 6 | $132 |
| Corium, LLC | 7 | $114 |
Products named: CAPLYTA, INVEGA SUSTENNA, REXULTI, Auvelity, VRAYLAR, LYBALVI, HETLIOZ, Xelstrym.
Industry payments across GA — which companies pay providers there.
